Home > Insider Trading > Filing (0001144204-14-059582)

Filing Details

Accession Number:: 0001144204-14-059582
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-10-03 22:01:15
Reporting Period:: 2014-10-01

Filing Date:: 2014-10-03
Accepted Time:: 2014-10-03 21:01:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1353128	Gayle Barbara Duncan	C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-10-01	1,299	$0.00	16,107	No	4	M	Direct
Common Stock	Acquisiton	2014-10-01	1,000	$31.90	17,107	No	4	M	Direct
Common Stock	Disposition	2014-10-01	900	$232.92	16,207	No	4	S	Direct
Common Stock	Disposition	2014-10-01	100	$234.87	16,107	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2014-10-01	1,299	$0.00	1,299	$0.00
Common Stock	Options to Purchase Common Stock	Disposition	2014-10-01	1,000	$0.00	1,000	$31.90

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
6,490			No	4	M	Direct
15,875		2023-05-07	No	4	M	Direct

Footnotes

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 17, 2014.
Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
On November 16, 2012, the reporting person was granted 20,769 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on October 1, 2014, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from January 1, 2015 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.
This option to purchase common stock was originally granted to the reporting person on May 7, 2013 (original amount: 22,500 shares). 25% of the shares of common stock underlying this option vested on January 1, 2014, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2017 (representing the vesting of approximately 2.0833% of the shares of common stock initially underlying these options on each such vesting date), subject to the terms and conditions of the award and the 2012 Plan.
This transaction was executed in multiple trades at prices ranging from $232.83 to $233. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.